Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). by Koskinas, Konstantinos C et al.
Journal Pre-proof
Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute
Coronary Syndromes (EVOPACS)
Konstantinos C. Koskinas, MD, MSc, Stephan Windecker, MD, Giovanni Pedrazzini,
MD, Christian Mueller, MD, Stéphane Cook, MD, Christian M. Matter, MD, Olivier
Muller, MD, Jonas Häner, MD, Baris Gencer, MD, Carmela Crljenica, MD, Poorya
Amini, PhD, Olga Deckarm, MD, Juan F. Iglesias, MD, Lorenz Räber, MD, PhD, Dik
Heg, PhD, François Mach, MD
PII: S0735-1097(19)36274-6
DOI: https://doi.org/10.1016/j.jacc.2019.08.010
Reference: JAC 26515
To appear in: Journal of the American College of Cardiology
Received Date: 25 July 2019
Revised Date: 9 August 2019
Accepted Date: 12 August 2019
Please cite this article as: Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM,
Muller O, Häner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Räber L, Heg D, Mach F,
Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes
(EVOPACS), Journal of the American College of Cardiology (2019), doi: https://doi.org/10.1016/
j.jacc.2019.08.010.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
3
3
1
3
4
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute 
Coronary Syndromes (EVOPACS)  
 
Konstantinos C. Koskinas, MD, MSc1; Stephan Windecker, MD1; Giovanni Pedrazzini, MD2; 
Christian Mueller, MD3; Stéphane Cook, MD4; Christian M. Matter, MD5; Olivier Muller, MD6; 
Jonas Häner, MD1; Baris Gencer, MD7; Carmela Crljenica, MD2; Poorya Amini, PhD8; Olga 
Deckarm, MD1; Juan F. Iglesias, MD7; Lorenz Räber, MD, PhD1; Dik Heg, PhD8; François 
Mach, MD7 
 
1Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, 
Switzerland  
2Cardiocentro, Lugano, Switzerland  
3Department of Cardiology, University Hospital Basel, Basel, Switzerland.  
4Department of Cardiology, Fribourg Hospital and University, Fribourg, Switzerland  
5Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, 
Switzerland  
6Service of Cardiology, Lausanne University Hospital, L usanne, Switzerland  
7Department of Cardiology, Geneva University Hospital, Geneva, Switzerland  
8CTU Bern, University of Bern, Bern Switzerland 
 
Short Title: Evlocumab in patients with ACS   
Disclosures: KCK has received consulting fees from Amgen and Sanofi. SW reports grants from 
Amgen Inc., Abbott, Bayer AG, Biotronik, Boston Scientific, Bristol Meyers Squibb, Edwards 
Lifesciences, Medtronic, Sinomed, and Polares. CM repo ts grants and personal fees from Sanofi 
and personal fees from Amgen. CMM reports research support from Amgen. JH received travel 
grants from Bayer. JFI received grants and personal fees from Biotronik, Philips Volcano, and 
Astra Zeneca, personal fees from Terumo, Medtronic, and Cardinal Health. LR received grants 
and personal fees from Abbott; personal fees from Agen, AstraZeneca, Sanofi and CSL 
Behring; grants from Boston Scientific, Biotronik, Heartflow, Sanofi, and Regeneron. The other 
authors have nothing to disclose.  
Funding: This work was supported by Amgen.    
Address for correspondence: 
Stephan Windecker, MD   
Professor and Chairman 
Department of Cardiology 
Bern University Hospital – INSELSPITAL 
University of Bern 
3010 Bern, Switzerland  
Tel: +41 31 632 4497 
Fax: +41 31 632 4771  
E-mail: stephan.windecker@insel.ch   
Twitter: @unibern   
ABSTRACT  
BACKGROUND While guidelines recommend in-hospital initiation of high-intensity statin 
therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol 
(LDL-C) target levels are frequently not attained. Evolocumab, a rapidly acting, potent LDL-C-
lowering drug, has not been studied in the acute phase of ACS.     
OBJECTIVES To assess the feasibility, safety, and LDL-C lowering efficacy of evolocumab 
initiated during the in-hospital phase of ACS.    
METHODS We conducted an investigator-initiated, randomized, double-blind, placebo-
controlled trial involving 308 patients hospitalized for ACS with elevated LDL-C levels (≥1.8 
mmol/L on high-intensity statin for at least 4 weeks; ≥2.3 mmol/L on low- or moderate-intensity 
statin; or ≥3.2 mmol/L on no stable dose of statin). Patients were randomly assigned 1:1 to 
receive subcutaneous evolocumab 420mg or matching placebo, administered in-hospital and 
after 4 weeks, on top of atorvastatin 40mg. The prima y endpoint was percentage change in 
calculated LDL-C from baseline to 8 weeks.  
RESULTS Most patients (78.2%) had not been on previous statin reatment. Mean LDL-C 
levels decreased from 3.61 mmol/L to 0.79 mmol/L at week 8 in the evolocumab group, and 
from 3.42 mmol/L to 2.06 mmol/L in the placebo group; the difference in mean percentage 
change from baseline was -40.7% (95% CI: -45.2 to -36.2; p<0.001). LDL-C levels <1.8 mmol/L 
were achieved at week 8 by 95.7% of patients in the evolocumab group vs. 37.6% in the placebo 
group. Adverse events and centrally adjudicated cariovascular events were similar in both 
groups.          
CONCLUSIONS In this first randomized trial assessing a PCSK9 antibody in the very high-risk 
setting of ACS, evolocumab added to high-intensity atin therapy was well tolerated and 
resulted in substantial reduction in LDL-C levels, rendering >95% of patients within currently 
recommended target levels.    
 
CONDENSED ABSTRACT  
The EVOPACS randomized, placebo-controlled trial asses ed the feasibility, safety, and LDL-C 
lowering efficacy of evolocumab on top of high-intesity statin in 308 patients hospitalized for 
ACS. The primary endpoint, percentage change in LDL-C from baseline to 8 weeks, was -
77.1±15.8% in the evolocumab group vs. -35.4±26.6% in the placebo group (p<0.001). More 
patients achieved an LDL-C target <1.8 mmol/L at week 8 with evolocumab vs. placebo (95.7% 
vs. 37.6%). The treatment was well tolerated; adverse events as well as centrally adjudicated 
cardiovascular events were similar in both groups.   
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Abbreviation list  
ACS = acute coronary syndrome  
ASCVD = atherosclerotic cardiovascular disease  
HDL = high density lipoprotein  
hs-CRP = high-sensitivity C-reactive protein   
LDL-C = low-density lipoprotein cholesterol  
NSTE-ACS = Non-ST-elevation acute coronary syndrome    
PCSK9 = proprotein convertase subtilisin/kexin type 9  
STEMI = ST-elevation myocardial infarction   
 
Clinical trial Registration: ClinicalTrials.gov Number: NCT03287609   
 
  
Introduction 
Patients with acute coronary syndromes (ACS) are at increased risk of recurrent 
ischaemic events, particularly during the early period following the index event (1). Lowering 
low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular morbidity and mortality in 
patients with atherosclerotic cardiovascular disease (ASCVD), with a magnitude of clinical 
benefit that is proportional to the reduction in LDL-C levels (2,3). In the context of ACS, early, 
in-hospital initiation of high-intensity statin treatment reduces the occurrence of early events and 
is recommended in current clinical practice guidelin s (4,5). While additional favourable 
biologic effects of statins on inflammation, endothelial function and coagulation have been 
postulated to contribute to the early clinical benefit observed in the acute period after ACS (6), 
that benefit is believed to be mediated, at least in part, by the reduction of LDL-related risk. In 
view of the delayed onset of action of statins and the high risk of event recurrence during the first 
weeks after ACS, and because of the frequent failure of ACS patients to attain treatment targets 
with intensive statin therapy alone (7), rapid and more potent lowering of LDL-C to levels even 
below currently recommended targets might be of potential therapeutic benefit in this setting. 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies have emerged as a new class of 
drugs that rapidly and effectively lower LDL-C levels. Evolocumab has been investigated in 
subjects without clinically evident ASCVD (8,9) or with stabilized ischaemic heart disease 
(10,11), and was shown to reduce major cardiovasculr events in the context of secondary 
prevention (11). Notably, patients were included in the FOURIER trial from several months up 
to 11 years following a myocardial infarction (12) The feasibility, safety, and LDL-lowering 
efficacy of PCSK9 antibody treatment initiated in the very high-risk, acute (within days) phase 
of ACS are presently unknown.  
Against this background, we conducted a randomized, placebo-controlled trial to assess 
evolocumab administered in-hospital on top of high-intensity statin therapy, compared with high-
intensity statin therapy alone, in patients presenting with ACS.      
Methods 
Study design and patients  
The study design has been previously described (13) and details are provided in the 
Online Appendix. Briefly, EVOPACS (NCT03287609) is an investigator-initiated, prospective, 
randomized, double-blind, placebo-controlled, parallel-group, phase III trial conducted at 7 
Swiss sites. We included patients presenting with ACS whose LDL-C levels were either higher 
than guideline-recommended targets (4) despite prior high-intensity statin therapy, or were not 
projected to decrease below these targets under newly-initiated high-intensity statin therapy. The 
protocol was approved by the institutional ethics committees, and all study participants provided 
written informed consent. 
Patients hospitalized for ACS [Non-ST-elevation ACS (NSTE-ACS) with symptom onset 
<72h or ST-elevation myocardial infarction (STEMI) with symptom onset <24h before 
screening] were potentially eligible. Inclusion and exclusion criteria are detailed in the Online 
Appendix. Screening was performed in stabilized patients upon hospital admission, and LDL-C 
was assessed locally at each site to determine eligibility. LDL-C levels at screening had to be 
≥1.8mmol/L (70 mg/dL) if patients were on stable (unchanged for ≥4 weeks before screening) 
treatment with high-intensity statin; or ≥2.3 mmol/L (90 mg/dL) in patients previously taking 
low- or moderate-intensity statin; or ≥3.2 mmol/l (125 mg/dL) in patients not on stable statin 
treatment. Allowed time intervals for study enrolment and study drug administration are 
summarized in Online Figure 1. Eligible patients were randomly assigned in a 1:1 ratio to 
receive evolocumab 420 mg every 4 weeks or placebo.  
Procedures and study interventions  
The study drug was administered at baseline as early as possible (within ≤24 hours) 
following randomisation. Among patients who underwent clinically indicated coronary 
angiography (with or without revascularization), administration of the study drug before 
angiography was favoured whenever possible, but administration after coronary angiography 
was also allowed. Blood samples were obtained at baseline for assessment of fasting lipids. The 
second study drug administration was performed during a visit at 4 weeks, and the final clinical 
visit was scheduled at 8 weeks. 
Patients in both groups were planned to receive atorvastatin 40mg/day throughout the 
study. For patients who had been on a more potent satin regimen (atorvastatin >40mg or 
rosuvastatin >20mg), the background therapy was atorv statin 80mg/day. Measurement of lipid 
levels, adjustments to statin therapy, and addition of on-statin lipid-lowering therapies were 
discouraged throughout the study. Enrolled patients were treated for the ACS event in 
accordance with current guidelines, including medical treatment with or without coronary 
angiography and revascularization [percutaneous coronary intervention (PCI) or coronary artery 
bypass (CABG) surgery].  
Outcomes 
The primary endpoint was percentage change in calculated LDL-C from baseline to 8 
weeks. Other efficacy lipid measurements included total cholesterol, non–high-density 
lipoprotein (HDL) cholesterol, triglycerides, HDL cholesterol, apolipoproteins B and A1, and 
lipoprotein(a). Fasting lipids at baseline, 4 weeks and 8 weeks were measured at a central core 
laboratory (Bern University Hospital, Bern, Switzerland). The LDL-C level was calculated with 
the use of the Friedewald formula. Secondary endpoints were adverse events (AEs) and serious 
adverse events (SAEs) from baseline to 8 weeks. Cardiovascular events were adjudicated by an 
independent, blinded Clinical Events Committee (CEC) and included death, myocardial 
infarction, coronary revascularization, hospitalization for recurrent ACS, hospitalization for heart 
failure, and cerebrovascular events (stroke or transient ischaemic attack). Exploratory endpoints 
reported herein included change in inflammatory biomarkers [high-sensitivity C-reactive protein 
(hsCRP), interleukin (IL)-1β, IL-6] from baseline to 8 weeks.  
Statistical analysis  
The study was designed as a superiority trial powered for the primary endpoint. 
Assuming an average LDL-C reduction of 30% in placebo (atorvastatin 40mg) arm and 44% in 
the active (evolocumab plus atorvastatin 40mg) arm, nd adopting a common standard deviation 
of 36%, a total sample size of 280 patients would provide statistical power of 90% at 5% 
significance level. Anticipating a dropout rate of 10% at 8 weeks, enrolment of 308 patients was 
planned (154 per arm).  
Comparisons of baseline characteristics were performed using t-tests, Fisher’s exact 
tests, and chi-square tests. Efficacy and safety analyses were performed on the full analysis 
set, which included all randomized patients who received at least one dose of the study drug. 
Analysis of the primary endpoint was conducted with a linear mixed effects model adjusting 
for presence of stable statin treatment at baseline (within ≥4 weeks prior to screening) as a 
fixed effect, and study center as a random effect. Analysis was based on the intention-to-treat 
(ITT) principle. For safety outcomes, missing data were not imputed, and adverse events were 
summarized by treatment group using descriptive statistics with rate ratios from Mantel-Cox 
regression (first event of each type), or Poisson regression (number of events of each type), 
with the time-at-risk equivalent to date of 8-week follow-up or death. Pre-specified subgroup 
analyses were performed in relation to pre-randomization statin treatment (yes/no), clinical 
presentation (STEMI vs. NSTE-ACS), age, gender, and baseline LDL-C ≥ vs. < median. Tests 
are two-sided throughout and a p-value below 5% was considered as significant. Analyses 
were performed with Stata 15.1 (StataCorp LLC, TX77845, USA).  
The study protocol was developed by the Steering Committee. The Clinical Trials Unit 
Bern, an academic research organization, monitored th  progress of the trial, had full access to 
the complete database, and independently generated all analyses. The authors had full access to 
the data and vouch for the accuracy and completeness of the analyses as presented.   
Results  
Out of 3,581 patients screened (Online Table 1), 308 patients were enrolled between 
January 23, 2018, and March 08, 2019 and randomly assigned to receive evolocumab (n=155) or 
placebo (n=153). The majority (62%) of enrolled patients were screened for study participation 
within <24 hours of patient-reported symptom onset, and all within <72 hours (Online Figure 
1). Baseline patient characteristics were generally well balanced between groups (Table 1). 
Mean age was 60.8±11.3 years, 18.5% of patients were omen, 14% had a history of previous 
myocardial infarction, and 2.6% had peripheral arterial disease. Most patients (78.2%) had not 
been on stable statin treatment in the previous 4 weeks (76.3% were on no statin at baseline; 
Online Table 2). Mean calculated LDL-C levels at baseline were 3.51±0.97 mmol/L. Treatment 
of the index ACS event included PCI (84.1%), medical therapy alone (8.8%), or CABG (7.1%). 
One patient in the placebo group withdrew consent early and did not receive the study 
drug at baseline, leaving a full analysis set of 307 patients who received at least one dose of 
study drug. The final visit at 8 weeks occurred in 293 patients (95.1% of those randomised) 
(Figure 1 and Online Table 3). The proportion of patients receiving atorvastatin 40 or 80 mg 
was 94.8% at discharge, 95.5% at week 4, and 93.6% at week 8, without significant differences 
between groups (Online Table 2 and Online Figure 2).  
Efficacy 
Calculated LDL-C was available at baseline as well as at 8 weeks for assessment of the 
primary endpoint in 277 patients (90%) (Figure 1). Percentage change in calculated LDL-C from 
baseline to 8 weeks was -77.1±15.8% in the evolocumab group (from a mean 3.61 mmol/L to 
0.79 mmol/L) vs. -35.4±26.6% in the placebo group (from a mean 3.42 mmol/L to 2.06 
mmol/L), amounting to a last-squares mean difference of -40.7% between groups (95% CI -45.2 
to -36.2; p<0.001) (Table 2 and Online Figure 3). Consistent changes were observed in a pre-
specified analysis using multiple imputations for missing data (Online Table 4), as well as in an 
exploratory, previously published approach (11,14) using either calculated LDL-C, or directly 
measured LDL-C in cases of calculated LDL-C level <40 mg/dL or triglyceride level >400 
mg/dL (available in 290 patients, 94.2% of all) (Online Table 5).   
The reduction in LDL-C levels was evident at 4 weeks and maintained at 8 weeks 
(Figure 2). At 8 weeks, LDL-C was reduced to <1.8 mmol/L in 95.7% of patients in the 
evolocumab group as compared with 37.6% in the placebo group (Central Illustration). 
Subgroup analyses of the primary endpoint showed a gre ter percent reduction in calculated 
LDL-C with evolocumab vs. placebo among patients who had been on statin treatment (mean 
difference -55.8%, 95% CI -70.1 to -41.6) compared with those not on statin treatment at 
baseline (-36.5%, 95% CI -40.5 to -32.5; p-value for interaction <0.001), and consistently, a 
greater reduction in patients with LDL-C levels below median at baseline. LDL-C reductions 
were otherwise consistent in relation to type of ACS, gender, and age (Online Figure 4). 
Evolocumab compared with placebo significantly reduced other atherogenic lipid 
particles, with reductions of 26.5% in total cholesterol, 34.2% in apolipoprotein B, 34.6% in non-
HDL-C (p<0.001 for all comparisons), and 20% in triglycerides (p=0.024). Evolocumab raised 
HDL-C by 4.8% (p=0.03), without significant differences in changes in apolipoprotein A1 
(Table 2 and Online Table 6). We found a significantly greater absolute, but not relative 
reduction in lipoprotein(a) with evolocumab (Online Table 6). 
Safety  
The percentage of patients who experienced adverse events, serious adverse events, and 
adverse events leading to study drug discontinuation were similar between groups (Table 3). 
Musculoskeletal pain was the most common reported adverse event, occurring in 9 patients 
(5.8%) in the evolocumab and 4 patients (2.6%) in the placebo group (p=0.16). Other common 
events were diarrhea (3.9% vs. 2.0%), local injection site reaction (3.2% vs. 2.0%), and 
nasopharyngitis (2.6% vs. 2.0%). ALT increase > 3x ULN was reported in 2 patients (1.3%) in 
each group. Serious adverse events occurred in 7.7%vs. 7.2% of patients in the evolocumab and 
placebo group, respectively, and adverse events that led to study drug discontinuation occurred 
in 1.3% vs. 2.0% of patients (Online Tables 7 and 8). 
Two deaths were reported. A 75-year male patient presented with NSTE-ACS and was 
scheduled for CABG; the patient developed anterior STEMI on the day of scheduled surgery 
(study day 9), underwent emergent repeat coronary angiography (in cardiogenic shock) that 
showed acute occlusion of the proximal left anterior descending artery, and died during the 
intervention despite prolonged resuscitation. The second patient, a 76-year old male, presented 
with NSTE-ACS and underwent CABG combined with aortic valve replacement on study day 
11. The patient developed a series of complications (intraoperative rupture of the aortic root and 
right coronary ostium requiring composite graft implantation; two repeat surgical revisions for 
pericardial tamponade), developed progressive cardiogenic shock with multi-organ failure, and 
died 14 days after surgery (25 days after study enrolment). Both fatal events were in the 
evolocumab group, were judged to be unrelated to the study drug by the Data and Safety 
Monitoring Board, and adjudicated as cardiovascular death by the CEC (Online Table 9).  
Adjudicated CV events did not differ significantly between groups. The majority of 
events included coronary revascularization procedurs (72 patients), primarily planned staged 
procedures (32 patients in the evolocumab vs. 38 in the placebo group). Target-lesion 
revascularization was reported in one patient in the placebo group, and other, clinically indicated 
coronary revascularizations in two patients in the evolocumab group. Five patients (4 in the 
evolocumab group, including the two patients who died, and one in the placebo group) 
experienced recurrent MI (Online Table 10).  
Inflammatory biomarkers   
Mean levels of hsCRP decreased from baseline to 8 weeks from 6.6 mg/L to 2.5 mg/L, 
without significant differences between groups. Similarly, there was no difference in the change 
in IL-1β and IL-6 levels (Table 4 and Online Table 11).  
Discussion  
This study, the first reported trial of a PCSK9 inhibitor initiated in-hospital in patients 
presenting with ACS, showed that the addition of evolocumab 420mg once every 4 weeks to 
high-intensity statin, compared with high-intensity s atin alone, resulted in substantially greater 
reduction in LDL-C levels after 8 weeks. Treatment with evolocumab lowered mean LDL-C 
levels from 3.61 mmol/L to 0.79 mmol/L as early as 4 weeks after the index event, and enabled 
>95% of patients to achieve guideline-recommended LDL-C targets. The treatment was well 
tolerated during the short duration of the study, without significant imbalances in adverse events. 
In patients presenting with ACS, the current paradigm for lipid management favours a 
stepwise approach consisting of early initiation of high-intensity statin, followed by subsequent 
addition of ezetimibe, and ultimately consideration of PCSK9 inhibitor treatment if LDL-C 
levels remain elevated (4,5). With this approach, ACS patients with markedly elevat d LDL-C 
levels would be considered for PCSK9 inhibitor treatment only several months following their 
index event. However, it is during the early period after an ACS that the risk of recurrent 
ischaemic events is greatest (1). Early initiation of intensive statin therapy following an ACS has 
been shown to reduce the occurrence of early recurrnt events – within 4 weeks in the PROVE 
IT trial (6) and within 16 weeks in the MIRACL trial (15). In view of the delayed onset of action 
of statins, and considering that ACS patients frequently present with markedly elevated LDL-C 
levels (16) and fail to achieve recommended treatmen  targets despite potent statin treatment, 
there is an unmet need for early, intensive reduction of atherogenic lipids in properly selected 
patients in this very high-risk clinical setting. The EVOPACS study tested a novel approach of 
very early, in-hospital initiation of evolocumab in patients who either had uncontrolled LDL-C 
levels despite pre-existing high-intensity statin trea ment, or were not expected to reach the 
recommended treatment targets with such a treatment. The study met its primary endpoint and 
showed favourable safety and tolerability outcomes. Importantly, because the early clinical 
benefit of in-hospital initiation of statins in ACS patients is likely mediated by both lipid-
lowering and other pleiotropic effects (6,15), the positive prognostic impact of statins in the 
acute post-ACS period cannot be directly extrapolated to PCSK9 antibodies. Therefore, whether 
early initiation of a PCSK9 inhibitor on top of a statin during the acute ACS phase might 
translate into an incremental clinical benefit remains to be determined in properly designed 
studies.  
The present results build upon previous studies that investigated PCSK9 monoclonal 
antibodies in individuals with hypercholesterolemia without known ASCVD (8), patients with 
statin intolerance (17) or familial hypercholesterol mia (9), and patients with stable 
manifestations of ASCVD (10,11). The FOURIER trial showed that evolocumab significantly 
reduced the risk of cardiovascular events in patients with ASCVD (11), with greater risk 
reduction observed in patients closer to their index MI; notably, the median interval between 
index MI and study enrolment ranged from 4 months up to 11 years in FOURIER (12). Along 
the same lines, the ODYSSEY OUTCOMES trial assessed the cardiovascular effects of 
alirocumab in patients at least 1 month (median 2.6 months) after an ACS (14). 
The average 40.7% LDL-C reduction achieved with evolocumab vs. placebo in 
EVOPACS, as compared with approximately 60% in previous evolocumab trials (8-11,17), 
should be interpreted in light of essential differenc s regarding background statin treatment. 
Unlike previous studies, treatment with evolocumab could be initiated in EVOPACS in patients 
who were not taking statin at baseline. These patients amounted to 79% of all enrolled patients, 
and in fact reflect the majority of ACS patients in contemporary trials (18) and real-world 
clinical practice (16). This finding explains the considerably higher baseline LDL-C levels in 
EVOPACS compared with previous evolocumab studies, in which patients were already on 
optimized statin therapy at baseline. It also accounts for the 35.4% average reduction in LDL-C 
in the placebo group [as compared with practically no change in earlier investigations (11,14)], 
considering that the majority of placebo-treated patients had been statin-naïve and received high-
dose atorvastatin during the study. Along these lins, the treatment effect of evolocumab on 
LDL-C was greater in the context of pre-existing statin therapy (i.e. a subgroup that resembles 
patients in FOURIER and other evolocumab trials) compared with patients in whom evolocumab 
and statin were both initiated in the acute ACS setting (Online Figure 4). Focusing on the on-
treatment LDL-C levels in the evolocumab plus atorvastatin group compared with the 
atorvastatin-only group (2.1 vs. 0.8 mmol/L), our findings are consistent with the LDL-C 
reduction seen in trials where evolocumab was added to stable lipid-lowering therapy (8-12, 17).  
The incidence of adverse events was overall similar between groups during the short 
duration of the study. These results are consistent with safety and tolerability data from previous 
studies with evolocumab in more stable clinical settings. The rate of cardiovascular events was 
numerically higher in the evolocumab group but did not differ significantly between groups, and 
was comparable to contemporary ACS trials; these reults need to be interpreted in view of the 
modest sample size as well as the inclusion of broadly representative ACS patients with frequent 
comorbidities. The majority of adjudicated events icluded staged coronary revascularization 
procedures, in line with current evidence supporting reatment of the culprit lesion during the 
index ACS event and intervention in other significant lesions within the subsequent days or 
weeks (19). It should be noted that the study was not powered for cardiovascular outcomes or 
serious adverse events, and the effect of evolocumab on such events in the early post.-ACS 
period merits further investigation.  
Previous studies showed no effect of PCSK9 antibodies on CRP levels (11). Because 
earlier statin trials found considerably larger reductions in CRP in the context of acute ACS (20) 
compared with more stable ASCVD manifestations or individuals in primary prevention (21), 
and in view of the pathobiological implication of the PCSK9 enzyme in vascular inflammation 
(22), we hypothesized that evolocumab might suppress inflammation in the ACS setting. Our 
exploratory analyses of inflammatory biomarkers did not confirm this hypothesis. In view of the 
anti-inflammatory effects of statins as well as the association between greater reduction of CRP 
with statins and better clinical outcomes (20), the neutral effect of evolocumab on CRP levels 
found herein as well as in previous trials points to the potential added value of combining 
PCSK9 antibodies with statins as background therapy.  
This study has several limitations. Although the week-8 clinical visit was performed in 
95% of patients, amounting to half the attrition rate nticipated in our power analysis (10%), the 
primary endpoint could be analysed in 90% of patients. This was due to the fact that, unlike 
previous PCSK9 inhibitor studies that used calculated LDL-C as their primary endpoint (10), we 
had not pre-specified elevated triglyceride levels as an exclusion criterion, and the Friedewald 
equation could not be reliably applied in a number of patients at baseline and/or follow-up. 
However, an ancillary analysis that was available in 94.1% of all randomised patients, using 
directly measured LDL-C in cases of very high triglycerides or very low LDL-C, showed very 
consistent results. Although evolocumab reduces LDL-C levels rapidly (within days) (23), lipid 
levels were first measured 4 weeks after the first study drug administration; thus, we could not 
capture earlier effects of evolocumab in this study setting. Given the large number of endpoints 
measured, the potential of type I error cannot be definitively excluded. Finally, the study size 
was modest, and the study duration short; based on the present results, larger and longer-term 
studies should further investigate evolocumab in the acute ACS setting, also assessing potential 
effects on clinical outcomes.  
Conclusions  
In patients presenting with ACS, evolocumab initiated in-hospital on top of high-intensity 
statin therapy was well tolerated and resulted in substantial reduction in LDL-C levels after 8 
weeks. Treatment with evolocumab allowed rapid attainment of currently recommended target 
levels by >95% of patients as compared with one third of placebo-treated patients.    
  
CLINICAL PERSPECTIVES 
Competency in medical knowledge: In patients with ACS, early (in-hospital) initiation of 
evolocumab on top of high-intensity statin appears to be well tolerated and results in substantial 
reduction in LDL-C levels and rapid attainment of recommended LDL-C treatment targets.    
 Translational outlook: Further studies are needed to investigate whether very early LDL-C 
lowering treatment with PCSK9 antibodies added to statin therapy might translate to improved 
clinical outcomes following ACS.    
References  
1. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force 
for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-
Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.  
2. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et 
al. Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data 
from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.   
3. Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and nonstatin LDL-lowering 
medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized 
trials. Eur Heart J 2018;39:1172-80. 
4. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management 
of dyslipidaemias. Eur Heart J 2016;37:2999-3058.    
5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ 
ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Managemnt of Blood Cholesterol. J Am 
Coll Cardiol 2019;73:e285-e350.  
6. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in 
patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 trial. J Am Coll 
Cardiol 2005;46:1405-10. 
7. Reiner Ž, De Backer G, Fras Z, et al. Lipid lowering drug therapy in patients with coronary 
heart disease from 24 European countries. Findings from the EUROASPIRE IV survey. 
Atherosclerosis 2016;246:243-50.  
8. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal 
antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients 
with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, 
doseranging, phase 2 study. Lancet 2012;380:2007-17.  
9. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in 
heterozygous familial hypercholesterolaemia (RUTHERFO D-2): a randomised, double-blind, 
placebo-controlled trial. Lancet 2015;385:331-40.    
10. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in 
reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9.   
11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients 
with cardiovascular disease. N Engl J Med 2017;376:1 13-22.    
12. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical Benefit of Evolocumab by 
Severity and Extent of Coronary Artery Disease. Circulation 2018;138:756-66.   
13. Koskinas KC, Windecker S, Buhayer A, et al. Design of the randomized, placebo-controlled 
evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary 
syndromes (EVOPACS) trial. Clin Cardiol 2018;41:1513-20.   
14. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after 
Acute Coronary Syndrome. N Engl J Med 2018;379:2097-2107.  
15. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent 
ischemic events in acute coronary syndromes. JAMA 2001;285:1711-8.   
16. Gencer B, Koskinas KC, Räber L, et al. Eligibility for PCSK9 Inhibitors According to 
American College of Cardiology (ACC) and European Society of Cardiology/European 
Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. J Am Heart 
Assoc 2017;6(11).  
17. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers 
cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled 
phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2541-8.  
18. Berwanger O, Santucci EV, de Barros E, et al. Effect of Loading Dose of Atorvastatin Prior 
to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in 
Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA 
2018;319:1331-40.   
19. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial 
revascularization. Eur Heart J 2019;40:87-165.   
20. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin 
therapy. N Engl J Med 2005;352:20-8.   
21. Ridker PM, Danielson E, Fonseca FA, et al. Rosuva tatin to prevent vascular events in men 
and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.    
22. Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) 
secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 
2012;220:381-6.  
23. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density 
lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, 
ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on 
statins. J Am Coll Cardiol. 2012;60:1888-98.  
  
Figure Legends 
Central Illustration. Attainment of the LDL-C Treatment Target <1.8 mmol/L at 8 Weeks 
in ACS Patients Receiving Evolocumab or Placebo on Top of High-Intensity Statin. Patients 
presenting with ACS and elevated LDL-C levels received either guideline-recommended high-
intensity statin plus placebo sc, or high-intensity tatin plus evolocumab sc. At 8 weeks, more 
that 95% of evolocumab-treated patients had an LDL-C level <1.8 mmol/l as compared with one 
third of placebo-treated patients. The impact of early (in-hospital) initiation of PCSK9 antibody 
treatment added to statin on cardiovascular outcomes requires further investigation.  
Abbreviations: ACS = acute coronary syndrome; LDL-C = low-density lipoprotein cholesterol.   
Figure 1: Study Flowchart. Reasons for exclusion of patients are detailed in Online Table 1. 
AE = adverse event; LDL-C = low-density lipoprotein cholesterol.  
Figure 2: Changes in LDL-Cholesterol Levels over Time. (A) Shown are mean values in the 
two study groups; error bars indicate 95% confidence i tervals. Below the graph, the absolute 
and percentage reductions in calculated LDL-cholesterol level in the evolocumab group are 
compared with those in the placebo group, presented as least-squares means. (B) Mean 
percentage changes in calculated LDL-cholesterol (± standard deviations) from baseline to 4 
weeks and 8 weeks in the two study groups.  
  
Table 1 Baseline Characteristics   
  Evolocumab 
(n=155) 
Placebo 
(n=153) 
Age (years)  60.5±12.0 61.0±10.7 
Male gender, n (%)  128 (83)  123 (80) 
Body mass index (kg/m2) 26.9±4.0 27.8±3.9 
Diabetes mellitus, n (%) 23 (15) 24 (16) 
Insulin-treated  1 (1) 6  (4) 
Arterial hypertension, n (%) 79 (51) 85 (56) 
Active smoking, n (%) 64 (41) 46 (30) 
Previous myocardial infarction, 
n (%) 
24 (15) 19 (12) 
Previous PCI, n (%) 25 (16) 23 (15) 
Previous CABG, n (%) 5 (3) 4  (3) 
Peripheral arterial disease, n (%) 4 (3) 4 (3) 
History of stroke, n (%)  2 (1) 0 (0) 
History of TIA, n (%)  5 (3) 0 (0) 
History of malignancy, n (%)  13 (8) 10 (7) 
Statin treatment*, n (%)     
No statin  124 (80) 117 (76) 
Low- or moderate-intensity 
statin  
13 (8) 22 (14) 
High-intensity statin†   18 (12) 14 (9) 
Ezetimibe treatment, n (%)   6 (4) 9 (6) 
Time of symptom onset <24h, n 
(%) 
100 (65) 90 (59) 
Index ACS event, n (%)    
NSTE-ACS 88 (57) 107 (70) 
STEMI 67 (43) 46 (30) 
ACS = acute coronary syndrome; CABG = coronary artery bypass graft surgery; NSTE-ACS = 
non-ST-elevation acute coronary syndrome; PCI = percutaneous coronary intervention; STEMI 
= ST-elevation myocardial infarction; TIA = transient ischaemic stroke.  
*Stable (unchanged) in the past ≥4 weeks prior to study enrolment.   
†Atorvastatin ≥40mg, rosuvastatin ≥20mg, or simvastatin 80mg.  
Table 2 Efficacy Outcomes  
  Evolocumab Placebo Mean difference (95% 
CI)* 
p 
value 
Calculated LDL-C      
Baseline (mmol/L) 3.61±1.00 [146] 3.42±0.94 [148] 0.14 (-0.05 to 0.32)   
Week 8 (mmol/L) 0.79±0.46 [141] 2.06±0.63 [149] -1.27 (-1.40 to -1.14) <0·001 
Absolute change from baseline (mmol/L)  -2.83±1.02 [132] -1.35±1.04 [145] -1.43 (-1.63 to -1.22) <0·001 
% Change from baseline (primary 
endpoint)  
-77.1%±15.8% 
[132] 
-35.4%±26.6% [145] -40.7% (-45.2% to -36.2%) <0·001 
Calculated LDL-C <1.8 mmol/L at week 8, 
%  
95.7% [141] 37.6% [149] 57.8% (66.2% to 49·4%) <0·001 
Other lipids, % change from baseline to 
week 8   
    
Cholesterol   -51.8%±14.6% 
[140] 
-24.4%±19.3% [150] -26.5% (-29.9% to -23.1%) <0·001 
Apolipoprotein B  -63.6%±14.9% 
[137] 
-28.8%±23.4% [149] -34.2% (-38.2% to -30.2%) <0·001 
Non-HDL-C   -67.3%±15.4% 
[140] 
-31.7%±23.7% [150] -34.6% (-38.5% to -30.6%) <0·001 
Triglycerides   -16.4%±40.4% 
[140] 
4.5%±98.4% [150] -20.0% (-37.4% to -2.6%) 0·024 
HDL-C   9.5%±17.9% [140] 4.9%±19.7% [150] 4.8% (0.5 to 9.1%) 0.03 
Apolipoprotein A1 5.6%±15.5% [137] 3.5%±14.7% [148] 2.2% (-1.2% to 5.7%) 0.21 
Lipoprotein(a)   0.5%±67.6% [139] 10.4%±49.5% [150]  -10.4% (-38.3% to 17.6%) 0.47 
 
Data expressed as means or least-squares means ± standard deviations, or n (%). P-value of the randomized arm, using mixed models 
correcting for a random effect of study site and a fixed effect of stable statin treatment before randomization.   
 
*Evolocumab minus placebo. 
Table 3 Adverse Events   
  Evolocumab 
(n=155) 
Placebo 
(n=152)* 
p value 
Any adverse event    78 (50.3) 77 (50.7) 0.72 
Serious adverse event   12 (7.7) 11 (7·2) 0.84 
Adverse event resulting in study drug     
     discontinuation  
2 (1.3) 3 (2·0) 0.65 
Events of special interest        
ALT increase >3xULN 2 (1.3) 2 (1.3) 0.97 
Symptomatic overdose 0 (0.0) 0 (0.0)   
General allergic reaction 1 (0.6) 0 (0.0) 1.00 
Local injection site reaction  5 (3.2) 3 (2.0) 0.48 
Pregnancy  0 (0.0) 0 (0.0)   
Neurocognitive event 1 (0.6) 0 (0.0) 1.00 
Musculoskeletal pain 9 (5.8) 4 (2.6) 0.16 
Nasopharyngitis 4 (2.6) 3 (2.0) 0.71 
Diarrhoea  6 (3.9) 3 (2.0) 0.30 
Other  63 (40.6) 64 (42.1) 0.91 
Positively adjudicated events       
All-cause death 2 (1.3) 0 (0.0) 0.50 
 Cardiovascular death 2 (1.3) 0 (0.0) 0.50 
Myocardial infarction 4 (2.6) † 1 (0.7) 0.17 
Coronary revascularization 33 (21.3) 39 (25.7) 0.39 
 Target-lesion revascularization 0 (0.0) 1 (0.7) 0.50 
 Planned staged procedure  32 (20.6) 38 (25.0) 0.39 
 Other revascularization  2 (1.3) 0 (0.0) 0.50 
Cerebrovascular event (stroke / 
TIA)  
1 (0.6) 0 (0.0) 1.00 
Hospitalization for recurrent 
ACS  
0 (0.0) 1 (0.7) 
0.50 
Hospitalization for heart failure  0 (0.0) 0 (0.0)  
 
Number (proportion) of patients with each event type are reported, not counting multiple events 
of the same type. Fisher's exact tests in case of zr  events in one group.     
ACS = acute coronary syndrome; ALT = alanine aminotransferase; TIA = transient ischaemic 
attack; ULN = upper limit of normal.       
*Excluded is one patient randomly allocated to placebo who withdrew consent early and refused 
study drug injection and any study intervention.  
†Including two patients who died. 
TABLE 4 Inflammatory Biomarkers      
  Evolocumab 
(155) 
Placebo 
(152)  
Mean difference* 
(95% CI)  
p value 
Inflammatory biomarkers (change from baseline to 
week 8) 
    
% Change hsCRP  -14.9±255.7  -35.1±.111.7  19.6 (-25.2 to 64.5) 0.39 
hs-CRP level <2 mg/L at week 8 (%)  68.8%  69.3% -0.7 (-11·4 to 9·9) 0.89 
Change in interleukin-1β (pg/ml)    0.05±0.90 -0.01±0.89 0.06 (-0.14 to 0.27) 0.53 
Change in interleukin 6 (pg/ml)    9.95±14.62 9.34.±.15.23 0.59 (-2.87 to 4.05) 0.74 
 
hsCRP = high-sensitivity C-reacting protein.    
 
*Evolocumab minus placebo  
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Supplemental Methods 
 
1. Patient eligibility  
 
Inclusion Criteria  
- Male or female ≥ 18 years of age  
- Hospitalized for a recent ACS (unstable angina or NSTEMI within < 72 hours, STEMI within < 24 
hours prior to screening)  
- LDL-C levels defined as follows:  
• LDL-C ≥70 mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100 mg/dL (≥2.6 mmol/) in patients who 
have been receiving stable treatment with high-intensi y statin within ≥ 4 weeks prior to 
enrollment (i.e. continuous treatment that has not changed with regard to statin intensity over the 
past 4 weeks)  
• LDL-C ≥90 mg/dL (≥2.3 mmol/L) or non-HDL-C ≥120 mg/dL (≥3.1 mmol/) in patients who 
have been receiving stable treatment with low- or mderate-intensity statin within ≥ 4 weeks 
prior to enrollment (i.e. continuous treatment that s not changed with regard to statin intensity 
over the past 4 weeks)  
• LDL-C ≥125 mg/dL (≥3.2 mmol/L) or non-HDL-C ≥155 mg/dL (≥4.0 mmol/) in patients who 
are statin-naïve or have not been on a stable (unchanged) statin regimen for at least 4 weeks prior 
to enrollment.  
-Ability to understand the requirements of the study and to provide informed consent  
 
 
Exclusion criteria  
- Unstable clinical status (hemodynamic or electrical instability)  
- Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or 
atrial fibrillation or flutter with rapid ventricular response not controlled by medications in the past 3 
months prior to screening  
- Severe renal dysfunction, defined by estimated glomerular filtration rate <30 ml/min/1.73m2  
- Active liver disease or hepatic dysfunction, eithr reported in patient medical record or defined by 
asparate aminotransferase (AST) or alanine aminotrasferase (ALT) levels > 3x the upper limit of 
normal.  
- Reported intolerance to atorvastatin (any dose) OR statin intolerance defined by the following 
criteria: inability to tolerate at least 2 different statins (one statin at the lowest starting averag daily 
dose and the other statin at any dose); intolerance ssociated with confirmed, intolerable statin-related 
adverse effect(s) or significant biomarker abnormalities; symptom or biomarker changes resolution or 
significant improvement upon dose decrease or discontinuation; and symptoms or biomarker changes 
not attributable to established predispositions such as drug-drug interactions and recognized 
conditions increasing the risk of statin intolerance  
- Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel  
- Known sensitivity to any substances to be administered  
- Patients who previously received evolocumab or other PCSK9 inhibitor  
- Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to 
screening  
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- Treatment with systemic steroids or systemic cyclosporine in the past 3 months (e.g. intravenous, 
intramuscular or per os)  
- Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment 
of the Investigator  
- Patients who will not be available for study-required procedures in the judgment of the Investigator  
- Current enrollment in another investigational devic  or drug study  
- Active malignancy requiring treatment  
- Pregnant women. For female of childbearing potential (age <50 years and last menstruation within 
the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy, pregnancy is 
excluded by a pregnancy test prior to inclusion in the study.  
 
The rationale for the LDL-C eligibility thresholds in conjunction with pre-enrollment statin treatment 
status relates to the inclusion of patients who hadnot reached the guideline-recommended LDL-C 
target of 70 mg/dL (1.8 mmol/L)1 prior to screening while on previous statin statin treatment, or were 
not expected to reach the target with the effect of at rvastatin 40mg QD (background statin therapy 
for all patients during the study period). Thereby, additional lipid-lowering (evolocumab in the active 
treatment group) would be justified in these patients. The threshold of LDL-C levels 90mg/dL (2.3 
mmol/L) in patients who had been on low- or moderate intensity statin reflects the anticipated 
incremental LDL-C reduction when switching from low- or moderate statin (prior to enrollment) to 
atorvastatin 40mg QD during the study (estimated, on average, 22% incremental LDL-C reduction).2 
Similarly, the LDL-C threshold of 125 mg/dL (3.2 mmol/L) accounts for the LDL-C lowering effect 
of atorvastatin 40mg QD by 43%2; hence, in patients with LDL-C levels ≥125 mg/dl (3.2 mmol) 
without pre-enrollment stable statin treatment, LDL-C levels would still remain above target despite 
the expected effect of atorvastatin 40mg, and additional LDL-C-lowering by means of evolocumab 
would be justified.  
 
2. Randomisation and masking  
Eligible patients were randomly assigned in a 1:1 ratio to receive subcutaneous evolocumab 420 mg 
every 4 weeks or placebo. Allocation sequences werebas d on computer-generated random numbers. 
Sequences were generated by an independent statistici n and concealed using a central randomization 
system. To ensure a balanced allocation of treatment and control over time, randomization lists were 
generated in blocks of 2, 4, or 6 patients and to enf rce concealment, block size was generated at 
random. Randomization was stratified according to study center, and presence of stable statin 
treatment within ≥4 weeks prior to enrollment (yes/no). Patients, investigators, study personnel, and 
adjudicators were masked to treatment assignment. The members of the Data and Safety Monitoring 
Board (DSMB) had access to unmasked data. Masking of the study drug was accomplished by use of 
identical pens with solutions for injection that were indistinguishable in appearance.   
 
 
References  
1. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of 
Dyslipidaemias. Eur Heart J 2016;37(39):2999-3058. 
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Appendix Figures 
 
Appendix Figure 1. Upper panel: Protocol-defined time windows for enolment and administration 
of the investigational product (IP) at baseline in relation to the time of onset of symptoms in patients 
presenting with acute coronary syndromes (ACS). Lower panel: shown are the proportions of patients 
who were screened for study enrolment within <24 hours or between 24 and 72 hours of symptoms 
onset, stratified by type of ASC (STEMI vs. NSTE-ACS).   
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Appendix Figure 2. Proportion of patients receiving the protocol-defind stain regimen, atorvastatin 
40 or 80 mg (A); or high-intensity statin (B) over time. Blue color indicates the placebo group, and 
red color the evolocumab group. There were no significa t differences between the two treatment 
groups at any time point (see Appendix Table 2).      
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Appendix Figure 3. Frequency distribution of calculated LDL-C levels at b seline (A) and 8 weeks 
(B), absolute change (C), and percentage change (D) in calculated LDL-C between baseline and 8 
weeks in the placebo and evolocumab groups.   
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Appendix Figure 4. Subgroup analyses for the primary endpoint, percentage change in calculated LDL-C from baseline to 8 weeks, in relation to statin 
treatment at baseline; study center; type of ACS (STEMI vs. NSTE-ACS); age; gender; and calculated LDL-C at baseline ≥ vs. < the median. Stratification 
for baseline statin treatment was done according to presence or absence of stable (unchanged) statin treatment in the preceding 4 weeks prior to enrolment. 
Shown are means ± standard deviations (p-value frommixed models), interaction p-value testing for theint raction effect subgroup x randomised arm from 
full-factorial mixed model.       
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Appendix Tables 
Appendix Table 1. Reasons for not enrolling screened patients   
Reason  Number 
Screening LDL-C levels not meeting the protocol-defin d criteria  1,010 
Index ACS event not meeting the protocol definition (NSTE-ACS with symptoms onset 
within ≤72 hours, STEMI with symptoms onset within ≤24 hours prior to screening)  
723 
Unstable clinical status (hemodynamic or electrical instability) 250 
Patients would not be available for study-required procedures in the judgment of the 
investigator 
243 
Current enrollment in another investigational devic or drug study 151 
Active liver disease or hepatic dysfunction according to protocol criteria 118 
Severe renal dysfunction  93 
Treatment with systemic steroids or systemic cyclosporine in the past 3 months 83 
Active malignancy requiring treatment 77 
Known active infection or major hematologic, metabolic, or endocrine dysfunction in the 
judgment of the investigator 
71 
Intolerance to atorvastatin or statin intolerance acording to protocol criteria  43 
No ability to understand the requirements of the study abd provide informed consent in the 
judgment of the investigator  
27 
Known sensitivity to any substances to be administered during the study  25  
Known allergy to contrast medium, heparin, aspirin,t cagrelor or prasugrel 13 
Uncontrolled cardiac arrhythmia 12 
Patients who previously received evolocumab or other PCSK9 inhibitor 9 
Patient refusal  152 
Other reasons  171 
Total 3,271 
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Appendix Table 2. Lipid-lowering and antithrombotic medications at baseline and throughout the 
study  
  All patients Evolocumab Placebo P-value 
Baseline, n (%)  n=308 n=155 n=153   
Statin treatment    0.03 
No statin 235 (76) 121 (78) 114 (75) 0.50 
Low-intensity statin 5 (2) 4 (3) 1 (1) 0.37 
Moderate-intensity statin 32 (10) 9 (6) 23 (15) 0.009 
High-intensity statin 36 (12) 21 (14) 15 (10) 0.38 
Other lipid-lowering drugs         
Ezetimibe 15 (5) 6 (4) 9 (6) 0.44 
Fibrates 0 (0) 0 (0) 0 (0)   
Niacin 0 (0) 0 (0) 0 (0)   
Resins 1 (0) 1 (1) 0 (0) 1.00 
Aspirin 74 (24) 38 (25) 36 (24) 0.89 
Clopidogrel 9 (3) 4 (3) 5 (3) 0.75 
Ticagrelor 4 (1) 2 (1) 2 (1) 1.00 
Prasugrel 2 (1) 0 (0) 2 (1) 0.25 
Dipyridamole 0 (0) 0 (0) 0 (0)   
NOAC 6 (2) 5 (3) 1 (1) 0.21 
Vitamin K antagonists  4 (1) 2 (1) 2 (1) 1.00 
Discharge, n (%) n=306 n=154 n=152   
Statin treatment    0.53 
No statin 5 (2) 2 (1) 3 (2) 0.68 
Low-intensity statin 1 (0) 1 (1) 0 (0) 1.00 
Moderate-intensity statin 4 (1) 3 (2) 1 (1) 0.62 
High-intensity statin 296 (97) 148 (96) 148 (97) 0.75 
Atorvastatin 40mg 283 (92) 139 (90) 144 (95) 0.19 
Atorvastatin 40 or 80mg 290 (95) 143 (93) 147 (97) 0.20 
Other lipid-lowering drugs          
Ezetimibe 7 (2) 5 (3) 2 (1) 0.45 
Fibrates 0 (0) 0 (0) 0 (0)   
Niacin 0 (0) 0 (0) 0 (0)   
Resins 1 (0) 1 (1) 0 (0) 1.00 
Aspirin 293 (96) 146 (95) 147 (97) 0.57 
Clopidogrel 30 (10) 18 (12) 12 (8) 0.34 
Ticagrelor 214 (70) 104 (68) 110 (72) 0.38 
Prasugrel 35 (11) 16 (10) 19 (13) 0.59 
NOAC 13 (4) 9 (6) 4 (3) 0.26 
Vitamin K antagonists  8 (3) 4 (3) 4 (3) 1.00 
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Week 4, n (%)  n=291 n=144 n=147   
Statin treatment    0.56 
No statin 6 (2) 4 (3) 2 (1) 0.44 
Low-intensity statin 1 (0) 1 (1) 0 (0) 0.49 
Moderate-intensity statin 3 (1) 1 (1) 2 (1) 1.00 
High-intensity statin 281 (97) 138 (96) 143 (97) 0.54 
Atorvastatin 40mg 273 (94) 135 (94) 138 (94) 1.00 
Atorvastatin 40 or 80 mg 278 (96) 136 (94)  142 (97) 0.41  
Other lipid-lowering drugs         
Ezetimibe 8 (3) 4 (3) 4 (3) 1.00 
Fibrates 0 (0) 0 (0) 0 (0)   
Niacin 0 (0) 0 (0) 0 (0)   
Resins 0 (0) 0 (0) 0 (0)   
Aspirin 278 (96) 136 (94) 142 (97) 0.41 
Clopidogrel 33 (11) 18 (13) 15 (10) 0.58 
Ticagrelor 198 (68) 93 (65) 105 (71) 0.26 
Prasugrel 36 (12) 18 (13) 18 (12) 1.00 
NOAC 18 (6) 13 (9) 5 (3) 0.054 
Vitamin K antagonists  7 (2) 3 (2) 4 (3) 1.00 
Week 8, n (%) n=299 n=148 n=151   
Statin treatment    0.26 
No statin 9 (3) 7 (5) 2 (1) 0.10 
Low-intensity statin 1 (0) 1 (1) 0 (0) 0.49 
Moderate-intensity statin 6 (2) 3 (2) 3 (2) 1.00 
High-intensity statin 283 (95) 137 (93) 146 (97) 0.13 
Atorvastatin 40mg 273 (91) 133 (90) 140 (93) 0.42 
Atorvastatin 40 or 80 mg 280 (94)  135 (91)  145 (96)  0.10  
Other lipid-lowering drugs          
Ezetimibe 10 (3) 4 (3) 6 (4) 0.75 
Fibrates 0 (0) 0 (0) 0 (0)   
Niacin 0 (0) 0 (0) 0 (0)   
Resins 0 (0) 0 (0) 0 (0)   
Aspirin 285 (95) 140 (95) 145 (96) 0.59 
Clopidogrel 38 (13) 20 (14) 18 (12) 0.73 
Ticagrelor 192 (64) 91 (61) 101 (67) 0.34 
Prasugrel 41 (14) 19 (13) 22 (15) 0.74 
NOAC 16 (5) 11 (7) 5 (3) 0.13 
Vitamin K antagonists  8 (3) 4 (3) 4 (3) 1.00 
 
NOAC = new oral anticoagulants.   
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Appendix Table 3.  Completeness of follow-up and study drug administration in the EVOPACS trial   
  All patients 
(n=308) 
Evolocumab 
(n=155) 
Placebo 
(n=153) 
p value 
Baseline (index hospitalization)         
Study drug      
Refused injection and withdrew consent 1 (0.3%) 0   (0.0%) 1 (0.7%) 0.50 
Double-blind injection of study drug 307 (99.7%) 155 (100.0%) 152 (99.3%) 0.50 
Week 4         
Clinical visit 283 (91.9%) 137 (88.4%) 146 (95.4%) 0.035 
No clinical visit 25 (8.1%) 18 (11.6%) 7 (4.6%) 0.035 
Alive but did not want to come clinical visit  22 (7.1%) 16 (10.3%) 6 (3.9%) 0.044 
Patient had withdrawn consent earlier 1 (0.3%) 0   (0.0%) 1 (0.7%) 0.50 
Patient deceased 2 (0.6%) 2   (1.3%) 0 (0.0%) 0.50 
Study drug     
Double-blind injection of study drug  279 (90.6%) 135 (87.1%) 144 (94.1%) 0.05 
Week 8          
Clinical visit 293 (95.1%) 142 (91.6%) 151 (98.7%) 0.006 
No clinical visit 15 (4.9%) 13 (8.4%) 2 (1.3%) 0.006 
Alive but did not want to come to the clinic 12 (3.9%) 11 (7.1%) 1 (0.7%) 0.005 
Patient had withdrawn consent earlier 1 (0.3%) 0 (0. %) 1 (0.7%) 0.50 
Patient deceased 2 (0.6%) 2 (1.3%) 0 (0.0%) 0.50 
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Appendix Table 4. Pre-specified sensitivity analysis of the primary endpoint, percentage change in calculated LDL-C from baseline to 8weeks, using 
multiple imputations*  
 
  All patients Evolocumab Placebo Mean difference  
(95% confidence intervals)† 
p value 
Calculated LDL-C       
% Change from baseline  
to week 8   
-55.30% (-58.77% to -51.83%) -74.16% (-77.65% to -70.66%) -36.06% (-40.37% to -31.76%) -37.15% (-42.13% to -32.18%) <0.001 
* According to the protocol, a sensitivity analysis for the primary endpoint using multiple imputation t impute the primary endpoint was pre-specified 
if calculated LDL-C at 8 weeks was missing in more than 5% of the patients. Calculated LDL-C was not avail ble at week 8 in 18 patients (5.8% of all 
308 randomised patients).   
P-value of the randomised arm, using mixed models corre ting for a random effect of the site and a fixed effect of stable statin treatment 4 weeks before 
randomisation. Computations based on combining the results from 20 multiple imputed data sets using Rubin's rule. Imputations based on predictive 
mean matching to five nearest neighbours, using the following baseline variables: corneal arcus, xanthomas, thyroid dysfunction, eGFR, AST, ALT, 
ALP, ADP, TRAP, age, gender, BMI, systolic BP, diastolic BP; family history of CAD, peripheral arterial disease, diabetes mellitus, insulin-treated 
diabetes mellitus, arterial hypertension, hypercholesterolemia, smoking history, active smoker, history f MI, PCI, CABG, CAD, HF, stroke, TIA, 
malignancy, no vs medium vs high intensity statins in the 4 weeks before randomisation; and follow-up variables: clinical visit week 4, clinical visit 
week 8, adverse event leading to study drug discontinuation; lipid measurements imputed for baseline, w ek 4 and week 8 (if missing).   
† Evolocumab minus placebo.  
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Appendix Table 5. Exploratory analysis of the primary endpoint using calculated LDL-C, or directly measured LDL-C in cases of calculated LDL-C 
<40mg/dL or triglycerides >400 mg/dL   
 
  All patients Evolocumab Placebo Mean difference  
(95% confidence intervals)* 
p value 
Calculated or directly measured LDL-C       
Baseline (mmol/L)  3.53 ± 0.98 [306] 3.61 ± 0.99 [154] 3.44 ± 0.96 [152] 0.12 (-0.06 to 0.30) 0.20 
Week 8 (mmol/L) 1.53 ± 0.78 [291] 0.95 ± 0.44 [141] 2.07 ± 0.62 [150] -1.11 (-1.23 to -0.99) <0.001 
Absolute change from baseline (mmol/L) -1.99 ± 1.21 [290] -2.66 ± 1.00 [140] -1.37 ± 1.05 [150] -1.24 (-1.44 to -1.04) <0.001 
% Change from baseline   -53.08% ± 28.29% [290] -71.89% ± 15.35% [140] -35.52% ± 26.25% [150] -35.32% (-39.61% to -31.02%) <0.001 
LDL-C < 1.8 mmol/L at Week 8  66.0% [291] 95.7% [141] 38.0% [150] 57.9% (49.4% to 66.5%) <0.001 
Data expressed as means ± standard deviations or n (%)  
* Evolocumab minus placebo.  
 .   
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Appendix Table 6. Changes in lipids  
  All patients Evolocumab Placebo Mean difference  
(95% confidence intervals)  
p value 
Cholesterol at baseline (mmol/L) 5.41 ± 1.07 [306] 5.50 ± 1.11 [154] 5.31 ± 1.04 [152] 0.14 (-0.06 to 0.35) 0.17 
Cholesterol at week 4 (mmol/L) 3.20 ± 0.92 [280] 2.56 ± 0.57 [136] 3.80 ± 0.76 [144] -1.23 (-1.39 to -1.08) <0.001 
Absolute change from baseline (mmol/L)  -2.22 ± 1.30 [280] -2.94 ± 1.08 [136] -1.53 ± 1.10 [144] -1.36 (-1.58 to -1.15) <0.001 
% Change from baseline  -39.02% ± 19.83% [280] -52.12% ± 12.61% [136] -26.65% ± 17.31% [144] -24.72% (-27.71% to -21.73%) <0.001 
Cholesterol at week 8 (mmol/L) 3.26 ± 0.97 [291] 2.59 ± 0.66 [141] 3.89 ± 0.78 [150] -1.29 (-1.46 to -1.13) <0.001 
Absolute change from baseline (mmol/L) -2.15 ± 1.38 [290] -2.94 ± 1.13 [140] -1.42 ± 1.17 [150] -1.46 (-1.69 to -1.23) <0.001 
% Change from baseline  -37.64% ± 21.98% [290] -51.79% ± 14.62% [140] -24.44% ± 19.33% [150] -26.49% (-29.86% to -23.12%) <0.001 
HDL-C at baseline (mmol/L) 1.12 ± 0.29 [306] 1.11 ± 0.29 [154] 1.14 ± 0.29 [152] -0.03 (-0.10 to 0.03) 0.30 
HDL-C at week 4 (mmol/L) 1.16 ± 0.32 [280] 1.17 ± 0.32 [136] 1.15 ± 0.32 [144] 0.01 (-0.06 to 0.09) 0.72 
Absolute change from baseline (mmol/L) 0.04 ± 0.19 [280] 0.07 ± 0.18 [136] 0.02 ± 0.19 [144] 0.05 (0.01 to 0.09) 0.02 
% Change from baseline 4.68% ± 15.95% [280] 7.07% ± 15.92% [136] 2.42% ± 15.70% [144] 4.67% (0.97% to 8.36%) 0.01 
HDL-C at week 8 (mmol/L)  1.19 ± 0.32 [291] 1.20 ± 0.33 [141] 1.18 ± 0.32 [150] 0.02 (-0.05 to 0.09) 0.56 
Absolute change from baseline (mmol/L) 0.07 ± 0.21 [290] 0.09 ± 0.19 [140] 0.04 ± 0.22 [150] 0.05 (0.01 to 0.10) 0.02 
% Change from baseline   7.12% ± 18.98% [290] 9.54% ± 17.90% [140] 4.87% ± 19.73% [150] 4.82% (0.50% to 9.14%) 0.03 
Triglycerides at baseline (mmol/L) 1.74 ± 1.07 [306] 1.82 ± 1.24 [154] 1.65 ± 0.86 [152] 0.18 (-0.06 to 0.42) 0.14 
Triglycerides at week 4 (mmol/L) 1.39 ± 0.62 [280] 1.33 ± 0.62 [136] 1.43 ± 0.63 [144] -0.09 (-0.23 to 0.06) 0.23 
Absolute change from baseline (mmol/L) -0.35 ± 0.88 [280] -0.50 ± 0.99 [136] -0.22 ± 0.73 [144] -0.28 (-0.48 to -0.08) 0.007 
% Change from baseline  -6.29% ± 50.38% [280] -14.80% ± 38.85% [136] 1.75% ± 58.25% [144] -16.38% (-27.94% to -4.83%) 0.005 
Triglycerides at week 8 (mmol/L) 1.39 ± 0.73 [291] 1.33 ± 0.72 [141] 1.44 ± 0.74 [150] -0.10 (-0.26 to 0.07) 0.25 
Absolute change from baseline (mmol/L) -0.37 ± 1.03 [290] -0.53 ± 1.12 [140] -0.21 ± 0.92 [150] -0.31 (-0.55 to -0.08) 0.009 
% Change from baseline   -5.61% ± 76.73% [290] -16.4 % ± 40.39% [140] 4.46% ± 98.42% [150] -20.04% (-37.43% to -2.65%) 0.02 
Non-HDL-C at baseline (mmol/L) 4.28 ± 1.08 [306] 4.40 ± 1.13 [154] 4.17 ± 1.02 [152] 0.18 (-0.03 to 0.39) 0.098 
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Non-HDL-C at week 4 (mmol/L) 2.04 ± 0.89 [280] 1.39 ± 0.55 [136] 2.65 ± 0.69 [144] -1.25 (-1-39 to -1.1 ) <0.001 
Absolute change  from baseline (mmol/L) -2.26 ± 1.30 [280] -3.01 ± 1.07 [136] -1.55 ± 1.08 [144] -1.42 (-1.63 to -1.20) <0.001 
% Change from baseline  -50.10% ± 24.01% [280] -67.1 % ± 13.16% [136] -33.98% ± 20.57% [144] -32.30% (-35.69% to -28.92%) <0.001 
Non-HDL-C at week 8 (mmoll/L) 2.07 ± 0.95 [291] 1.39 ± 0.61 [141] 2.71 ± 0.73 [150] -1.32 (-1.47 to -1.16) <0.001 
Absolute change from baseline (mmol/L)  -2.22 ± 1.38 [290] -3.03 ± 1.12 [140] -1.46 ± 1.16 [150] -1.52 (-1.74 to -1.29) <0.001 
% Change from baseline  -48.85% ± 26.82% [290] -67.2 % ± 15.37% [140] -31.68% ± 23.65% [150] -34.57% (-38.51% to -30.63%) <0.001 
Lipoprotein(a) at baseline  (nmol/L) 68.56 ± 89.25 [305] 73.93 ± 94.49 [153] 63.16 ± 83.62 [152] 11.62 (-8.27 to 31.52) 0.25 
Lipoprotein(a) at week 8 (nmol/L) 69.09 ± 93.81 [291] 69.77 ± 97.23 [141] 68.44 ± 90.80 [150] 1.54 (-20.00 to 23.08) 0.89 
Absolute change from baseline (nmol/L)  0.89 ± 29.97 [289] -4.55 ± 32.95 [139] 5.92 ± 26.03 [150] -10.93 (-17.64 to -4.22) 0.001 
% Change from baseline  5.64% ± 121.47% [289] 0.51% ± 67.61% [139] 10.40% ± 49.54% [150] -10.37% (-38.33% to 17.59%) 0.47 
Apolipoprotein B at baseline  (g/L) 1.14 ± 0.29 [302] 1.17 ± 0.29 [151] 1.12 ± 0.29 [151] 0.04 (-0.02 to 0.09) 0.17 
Apolipoprotein B at week 8 (g/L) 0.59 ± 0.25 [291] 0.41 ± 0.17 [141] 0.76 ± 0.20 [150] -0.35 (-0.39 to -0.31) <0.001 
Absolute change from baseline (g/L)  -0.55 ± 0.35 [286] -0.76 ± 0.28 [137] -0.36 ± 0.31 [149] -0.39 (-0.45 to -0.33) <0.001 
% Change from baseline   -45.45% ± 26.36% [286] -63.62% ± 14.88% [137] -28.75% ± 23.41% [149] -34.18% (-38.21% to -30.16%) <0.001 
Apolipoprotein A1 at baseline (g/L) 1.34 ± 0.23 [301] 1.33 ± 0.23 [151] 1.36 ± 0.24 [150] -0.04 (-0.09 to 0.01) 0.14 
Apolipoprotein A1 at week 8 (g/L) 1.40 ± 0.26 [291] 1.40 ± 0.27 [141] 1.40 ± 0.25 [150] 0.00 (-0.05 to 0.06) 0.91 
Absolute change from baseline (g/L) 0.05 ± 0.19 [285] 0.06 ± 0.19 [137] 0.03 ± 0.19 [148] 0.03 (-0.01 to 0.08) 0.16 
% Change from baseline   4.49% ± 15.10% [285] 5.60% ± 15.47% [137] 3.47% ± 14.73% [148] 2.24% (-1.24% to 5.72%) 0.21 
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Appendix Table 7. Total number of events (with rate of events per patient-month at risk in brackets)   
 All patients  Evolocumab Placebo    
  No. of 
events 
Rate / person-months No. of 
events 
Rate / person-months No. of 
events 
Rate / person-months Incidence Rate Ratio 
[Evolocumab/Placebo] 
p value 
  n=307 573.6 person-months n=155 284.1 person-months n=152* 289.5 person-months   
Any adverse event   258 0.450 (0.398-0.508) 144 0.507 (0.431-0.596) 114 0.394 (0.328-0.473) 1.37 (1.04- .80) 0.025 
Non-serious adverse event 229 0.399 (0.351-0.454) 127 0.447 (0.376-0.532) 102 0.352 (0.290-0.428) 1.34 (1.00-1.79) 0.049 
Serious adverse event  29 0.051 (0.035-0.073) 17 0.060 (0.037-0.096) 12 0.041 (0.024-0.073) 1.54 (0.65-3. 2) 0.32 
Adverse event  resulting in study   
    drug discontinuation  
5 0.009 (0.004-0.021) 2 0.007 (0.002-0.028) 3 0.010 (0.003-0.032) 0.68 (0.11-4.07) 0.672 
Events of special interest         
ALT increase >3x ULN  4 0.007 (0.003-0.019) 2 0.007 ( .002-0.028) 2 0.007 (0.002-0.028) 1.02 (0.14-7.24) 0.98 
Symptomatic overdose 0  0  0    
General allergic reaction 1 0.002 (0.000-0.012) 1 0.004 (0.000-0.025) 0   1.00 
Local injection site reaction  9 0.016 (0.008-0.030) 5 0.018 (0.007-0.042) 4 0.014 (0.005-0.037) 1.19 (0.28-5.06) 0.81 
Pregnancy  0  0  0    
Neurocognitive event 1 0.002 (0.000-0.012) 1 0.004 (0.000-0.025) 0   1.00 
Musculoskeletal pain 14 0.024 (0.014-0.041) 9 0.032 (0.016-0.061) 5 0.017 (0.007-0.041) 1.80 (0.58-5.64) 0.31 
Nasopharyngitis 7 0.012 (0.006-0.026) 4 0.014 (0.005- . 38) 3 0.010 (0.003-0.032) 1.36 (0.30-6.07) 0.69 
Diarrhoea  10 0.017 (0.009-0.032) 7 0.025 (0.012-0.052) 3 0.010 (0.003-0.032) 2.40 (0.57-10.11) 0.23 
Other  183 0.319 (0.276-0.369) 98 0.345 (0.283-0.421) 85 0.294 (0.237-0.363) 1.22 (0.89-1.67) 0.22 
Positively adjudicated events         
All-cause death 2 0.003 (0.001-0.014) 2 0.007 (0.002- . 28) 0    
Cardiovascular death 2 0.003 (0.001-0.014) 2 0.007 ( .002-0.028) 0    
Myocardial infarction 5 0.009 (0.004-0.021) 4 0.014 (0.005-0.038) 1 0.003 (0.000-0.025) 4.08 (0.46-36.47) 0.21 
Coronary revascularisation 79 0.138 (0.110-0.172) 39 0.137 (0.100-0.188) 40 0.138 (0.101-0.188) 0.99 (0.64-1.54) 0.98 
Target-lesion revascularisation 1 0.002 (0.000-0.012) 0  1 0.003 (0.000-0.025)   
Staged 76 0.132 (0.106-0.166) 37 0.130 (0.094-0.180) 39 0.135 (0.098-0.184) 0.97 (0.62-1.52) 0.88 
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Other revascularisation 2 0.003 (0.001-0.014) 2 0.007 ( .002-0.028) 0   0.50 
Cerebrovascular Event 1 0.002 (0.000-0.012) 1 0.004 ( .000-0.025) 0   1.00 
Hospitalization for recurrent ACS  1 0.002 (0.000-0.012) 0   1 0.003 (0.000-0.025)   0.50 
Hospitalization for heart failure 0  0  0    
Rate ratios are estimated using the Poisson regression with two-sided p-values from Wald test. Fisher's xact test on the raw counts in case no events in 
one randomised treatment arm.            
ACS = acute coronary syndrome; ALT = alanine aminotransferase; ULN = upper limit of normal.        
  
* Excluded is one patient randomly allocated to placebo who immediately withdrew consent and refused stu y drug administration.    
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Appendix Table 8. Description of adverse events that resulted in study drug discontinuation in five patients  
Patient Randomised 
arm 
Study drug 
administrations 
Description of adverse event  Blinded assessment of 
relationship of adverse 
event with study drug * 
Serious 
adverse 
event  
Patient # 1  
 
Evolocumab Administered at 
baseline but not 
at week 4.  
69-year old male patient presented with NSTE-ACS. Coronary artery bypass surgery was 
performed 3 days after study enrolment and baseline study drug admiration. The patient was 
discharged 12 days after study enrolment and receivd aspirin and rivaroxaban due to newly 
(in-hospital) diagnosed atrial fibrillation. At 27 days after study enrolment the patient was 
hospitalized in another hospital with anemia (hemoglobin drop from 11.9 to 7.8 g/L) and 
gastrointestinal bleeding. The patient received erythrocyte transfusion, and rivaroxaban was 
discontinued.  
The week 4 clinical visit and week 4 study drug administration were not performed, as the 
patients was hospitalized in another hospital during the allowed time window. The patient 
returned for the week 8 clinical visit.    
• Local Investigator: 
No/Unlikely 
  
• DSMB: No/Unlikely 
Yes 
Patient #2 
 
Evolocumab Administered at 
baseline but not 
at week 4. 
71-year old male patient presented with acute STEMI. Coronary artery bypass surgery was 
performed 4 days after study enrolment and baseline study drug administration. The patient 
was discharged 10 days after study enrolment. 11 days later (i.e. 21 days after study enrolment) 
the patient presented to the emergency room with pleura  pain and fever and was hospitalized 
for pleural effusion presumably in the context of pst-operative Dressler syndrome. Pleural 
puncture resulted in iatrogenic hemo- and pneumothorax that prolonged hospitalization. During 
the hospitalization, the patient was further diagnosed with herpes simples type 1 infection, 
necessitating treatment with acyclovir.   
The week 4 clinical visit and week 4 study drug administration were not performed, as the 
patients was hospitalized during the allowed time window. The patient did not return for the 
week 8 clinical visit.   
• Local Investigator:  
     No/Unlikely  
 
• DSMB: No/Unlikely 
Yes 
Patient #3  
 
Placebo Administered at 
baseline but not 
at week 4.  
51-year old male patient presented with acute anterior STEMI and underwent primary PCI with 
stenting of the mid left anterior descending artery. At 25 days after study enrolment and 
baseline study drug administration, the patient was hospitalized for suspected upper 
gastrointestinal bleeding (melena and anemia). Endoscopic control showed erosive gastritis. 
The patient received erythrocyte transfusion, was st bilized and discharged after 8 days (day 33 
after study enrolment).  
The week 4 clinical visit and week 4 study drug administration were not performed, as the 
patients was hospitalized during the allowed time window. The patient returned for the week 8 
• Local Investigator:  
     No/Unlikely  
 
• DSMB: No/Unlikely 
Yes  
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clinical visit.   
Patient #4  
 
Placebo Administered at 
baseline but not 
at week 4. 
68-year old male patient presented with acute STEMI and underwent primary PCI. The patient 
reported persistent cough that started 7 days after study enrolment and baseline study drug 
administration. The patient consulted his general pr ctitioner, who recommended stopping the 
ACE-inhibitor (ramipril). Because the symptoms had not improved at the week-4 study visit, it 
was decided not to perform the study drug administration.  
 
The patient returned for the week 8 clinical visit.      
N/A * No 
Patient #5  
 
Placebo Administered at 
baseline but not 
at week 4. 
54-year old male patient presented with acute NSTE-ACS and underwent PCI. The patient 
reported a rash 5 days following study enrolment and baseline study drug administration. The 
rash disappeared 5 days later with no medical treatm nt (only moisturizing cream was applied 
locally).  
 
The week-4 study visit was performed, but the local investigator advised against the 
administration of the week-4 study drug. The patient r turned for the week 8 clinical visit.   
N/A *  No  
 
DSM = Data and Safety Monitoring Board.   
* As per protocol, the relationship between an adverse vent and the study drug was assessed by the local investigator as well as the DSMB in case of repo ted 
serious adverse events.    
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Appendix Table 9. Narratives for two deaths that occurred during the EVOPACS study   
Patient Randomised 
arm 
Description  Blinded assessment of 
relationship of death 
with study drug 
Patient # 1  
 
Evolocumab A 75-year-old male patient with known coronary artery disease (history of myocardial infarction and PCI) presented with 
NSTE-ACS. Symptoms had reportedly began 2 days before. Cardiovascular risk factors included active smoking, diabetes 
mellitus, arterial hypertension, and hypercholesterolemia (LDL cholesterol 2.8 mmol/l at baseline under atorvastatin 20mg). 
Baseline medical treatment included aspirin, amlodipin, lisinopril, and atorvastatin. The patient was enrolled in the study and 
received the baseline study drug on the same day of dmission in the hospital. Coronary angiography showed complex three-
vessel coronary artery disease (chronic occlusion of the right coronary artery, significant stenoses in the proximal left anterior 
descending artery and first marginal branch). The patient was scheduled for coronary artery bypass surgery after 7 days, and 
remained in-hospital. On the day of the scheduled surgery (day 7 after study enrolment), the patient rpo ted retrosternal pain. 
ECG showed ST elevation in anterior and inferior leads. The patient underwent urgent coronary angiography, which showed 
acute occlusion of the proximal left anterior descending artery, occlusion of the right circumflex artery, and a critical lesion in 
the first marginal branch. The patient developed car iogenic shock and, during attempted recanalization of the left anterior 
descending artery, developed rhythm disorders and crdiac arrest. Despite resuscitation (30 minutes compression) and 
attempted extracorporeal membrane oxygenation (ECMO), the patient died with electromechanical dissociation.  
 
The CEC adjudicated the death as cardiovascular.  
• Local Investigator: 
No/Unlikely 
  
• DSMB: No/Unlikely 
Patient #2 
 
Evolocumab A 76-year-old patient with a history of atrial fibrillation presented with NSTE-ACS. Cardiovascular risk factors included 
arterial hypertension, obesity (BMI 32.6), and hypercholesterolemia (LDL-C 3.86 mmol/l under no lipid-lowering therapy). The 
patient was enrolled in the study and received the baseline study drug on the same day of hospital admission, on the same day 
and following the performance of coronary angiography. Angiography showed complex three-vessel disease, and aortic valve 
stenosis was found in echocardiography with preserved left ventricular function (LVEF 58%). The patient was transferred to 
another hospital for performance of cardiac surgery. The patient remained in-hospital, and surgery (quadr ple coronary bypass 
grafting and concomitant aortic valve replacement) was performed at 11 days after study enrolment. Surgery was complicated 
by intraoperative rupture of the calcific aortic root and the right coronary ostium requiring composite graft implantation 
(Bentall procedure) with re-implantation of the right coronary artery using a short saphenous venous graft. Postoperatively the 
patient remained hemodynamically unstable requiring hemodynamic support with a veno-arterial extracorporeal membrane 
oxygenation device (ECMO), and underwent two repeat surgical revisions for pericardial tamponade. Right ventricular failure 
was the leading presentation. Coronary angiography six days after surgery (17 days after study enrolment) r vealed an occluded 
venous graft to the right coronary artery; however, no repeat revascularization was attempted. Progressive cardiogenic shock 
with multi-organ failure (ischemic hepatic failure, acute kidney failure requiring hemodialysis) evolved and six days later, 
replacement of the veno-arterial ECMO by a percutaneous right ventricular assist device was attempted. This immediately 
• Local Investigator:  
No/Unlikely  
 
• DSMB: 
No/Unlikely 
 22  
resulted in acute left ventricular decompensation refractory to further medical treatment. The patient died 14 days after surgery 
(25 days after study enrolment).   
The CEC adjudicated the death as cardiovascular.  
 
CEC = Clinical Events Committee; DSMB = Data and Safety Monitoring Board.    
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Appendix Table 10. Narratives for adjudicated myocardial infarctions that occurred in five patients during the EVOPACS study   
Patient Randomised 
arm 
Description  Blinded assessment of 
relationship of death 
with study drug * 
Patient # 1  
 
 
 
Evolocumab  An 81-year-old female patient without known coronary tery disease presented with NSTE-ACS. Cardiovascul r risk factors 
included previous smoking and hypercholesterolemia (LDL cholesterol 4.1 mmol/l at baseline under no statin treatment). The 
patient had not been on regular medical treatment at the time of study enrolment. Coronary angiography was performed on the 
day of study enrolment and showed three-vessel coronary artery disease; the culprit lesion in the right coronary artery was 
treated with PCI at baseline. Additional significant stenoses in the proximal and mid left anterior descending artery and in the 
proximal left circumflex artery were scheduled for an elective, staged PCI after 4 weeks. The elective ardiac catheterization 
occurred 28 days after the index procedure (study day 28). The lesions identified at the index procedur  were treated by means 
of stenting with a total of 5 drug-eluting stents. Laboratory control on the following day (study day 29) showed significant 
increase in cardiac biomarkers (high-sensitivity troponin).  
 
This event was not reported as a myocardial infarction by the investigators and was therefore not evaluated by the DSMB. The 
event (occurring on study day 29) was adjudicated by the CEC as a case of myocardial infarction.   
 
• Local Investigator: 
n/a 
  
• DSMB: n/a  
Patient #2 
 
 
 
 
 
Placebo  A 71-year-old female patient with known know  coronary artery disease (history of PCI in the left anterior descending artery) 
presented with NSTE-ACS. Cardiovascular risk factors included arterial hypertension, obesity (BMI 31.0), and 
hypercholesterolemia (screening LDL-C 5.9 mmol/l under no lipid-lowering therapy). The patient was enrolled in the study and 
received the baseline study drug on the same day and following the performance of coronary angiography. Coronary 
angiography identified a significant restenotic lesion in the proximal left anterior descending artery (in-stent restenosis) as the 
culprit lesion of the index event. The lesion was trea ed by means of dilatation with a drug-eluting balloon, without 
implantation of a stent. The patient was discharged on the following day (one day after study enrolment and coronary 
angiography). The patient returned 28 days after study enrolment for the week-4 clinical visit (study rug administration and 
week-4 laboratory testing). Four days after the week-4 visit (32 days after study enrolment), the patient experienced symptoms 
of chest pain, and laboratory testing showed significant increase of cardiac biomarkers. A diagnosis of NSTE-ACS was made. 
Coronary angiography on study day 33 showed a significa t restenotic lesion in the proximal left anterior descending artery / 
first diagonal branch bifurcation that was treated with PCI and implantation of drug-eluting stents.   
 
The event was reported by the local investigators as myocardial infarction treated with PCI. The CEC adjudicated the event as 
myocardial infarction, repeat coronary revascularization (target-lesion revascularization), and hospitalization for recurrent ACS.  
 
The patient returned for the week-8 clinical visit 60 days after study enrolment.   
• Local Investigator:  
No/Unlikely  
 
• DSMB: 
No/Unlikely 
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Patient #3 
 
 
 
 
 
Evolocumab  A 51-year-old male patient without known known coronary artery disease presented with NSTE-ACS. Cardiovascular risk 
factors included arterial hypertension, active smoking, and hypercholesterolemia (screening LDL-C 3.3 mmol/l under no lipid-
lowering therapy). The patient was enrolled in the study and received the baseline study drug on the same day and prior to the 
performance of coronary angiography. Coronary angiography showed significant stenoses in the mid left anterior descending 
artery, proximal left circumflex artery and first marginal branch. Coronary artery bypass surgery was decided after discussion 
within the heart team and with the patient, but eventually due to clinical instability, it was decided to proceed with percutaneous 
revascularization in two steps.  Two days after study enrolment and after the first coronary angiography, angioplasty in the left 
anterior descending artery was performed with implantation of two drug-eluting stents. Four days later (six days after enrolment 
in the study) the lesions in the left circumflex artery and first marginal branch were treated with angioplasty and stenting. On 
the same day and following the intervention (study da 6), the patient developed retrosternal chest pain, with increase of cardiac 
enzymes and new ECG changes. The patient was treated with optimization of medical therapy. Repeat coronary angiography 
was performed on study day 12 that showed  significant stenoses in the first marginal branch and distal circumflex artery that 
were treated with PCI.    
 
A myocardial infarction event was not reported by the local investigators and was therefore not evaluated by the DSMB. The 
CEC adjudicated the event occurring on study day 6 s myocardial infarction.  
 
The patient returned for the week-4 visit 28 days after study enrolment, and for the week-8 clinical visit 61 days after study 
enrolment.    
 
• Local Investigator: 
n/a 
  
• DSMB: n/a 
Patient #4  
 
 
 
Evolocumab  This event occurred in a patient who died (see patient #1 in Appendix Table 9).  
 
A 75-year-old male patient with known coronary artery disease (history of myocardial infarction and PCI) presented with 
NSTE-ACS. Symptoms had reportedly began 2 days before. Cardiovascular risk factors included active smoking, diabetes 
mellitus, arterial hypertension, and hypercholesterolemia (LDL cholesterol 2.8 mmol/l at baseline under atorvastatin 20mg). 
Baseline medical treatment included aspirin, amlodipin, lisinopril, and atorvastatin. The patient was enrolled in the study and 
received the baseline study drug on the same day of dmission in the hospital, Coronary angiography showed complex three-
vessel coronary artery disease (chronic occlusion of the right coronary artery ,significant stenoses in the proximal left anterior 
descending artery and first marginal branch). The patient was scheduled for coronary artery bypass surgery after 7 days, and 
remained in-hospital. On the day of the scheduled surgery (day 7 after study enrolment), the patient rpo ted retrosternal pain. 
ECG showed ST elevation in anterior and inferior leads. The patient underwent urgent coronary angiography, which showed 
acute occlusion of the proximal left anterior descending artery, occlusion of the right circumflex artery, and a critical lesion in 
the first marginal branch. The patient developed car iogenic shock and, during attempted recanalization of the left anterior 
descending artery, developed rhythm disorders and crdiac arrest. Despite resuscitation (30 minutes compression) and 
attempted extracorporeal membrane oxygenation (ECMO), the patient died with electromechanical dissociation.  
 
The event was reported by the local investigators as myocardial infarction and adjudicated by the CEC as myocardial infarction.  
• Local Investigator: 
No/unlikely  
  
• DSMB: No/unlikely  
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Patient #5 
 
  
Evolocumab  This event occurred in a patient who died (see patient #2 in Appendix Table 9).  
 
A 76-year-old patient with a history of atrial fibrillation presented with NSTE-ACS. Cardiovascular risk factors included 
arterial hypertension, obesity (BMI 32.6), and hypercholesterolemia (LDL-C 3.86 mmol/l under no lipid-lowering therapy). The 
patient was enrolled in the study and received the baseline study drug on the same day of hospital admission, on the same day 
and following the performance of coronary angiography. Angiography showed complex three-vessel disease, and aortic valve 
stenosis was found in echocardiography with preserved left ventricular function (LVEF 58%). The patient was transferred to 
another hospital for performance of cardiac surgery. The patient remained in-hospital, and surgery (quadr ple coronary bypass 
grafting and concomitant aortic valve replacement) was performed at 11 days after study enrolment. Surgery was complicated 
by intraoperative rupture of the calcific aortic root and the right coronary ostium requiring composite graft implantation 
(Bentall procedure) with re-implantation of the right coronary artery using a short saphenous venous graft. Postoperatively the 
patient remained hemodynamically unstable requiring hemodynamic support with a veno-arterial extracorporeal membrane 
oxygenation device (ECMO), and underwent two repeat surgical revisions for pericardial tamponade. Right ventricular failure 
was the leading presentation. Coronary angiography six days after surgery (17 days after study enrolment) r vealed an occluded 
venous graft to the right coronary artery; however, no repeat revascularization was attempted. Progressive cardiogenic shock 
with multi-organ failure (ischemic hepatic failure, acute kidney failure requiring hemodialysis) evolved and six days later, 
replacement of the veno-arterial ECMO by a percutaneous right ventricular assist device was attempted. This immediately 
resulted in acute left ventricular decompensation refractory to further medical treatment. The patient died 14 days after surgery 
(25 days after study enrolment).   
 
A myocardial infarction event was not reported by the local investigators and was therefore not evaluated by the DSMB. The 
CEC adjudicated the event occurring on study day 17 (six days after surgery, day of performance of the repeat coronary 
angiography) as myocardial infarction.     
 
• Local Investigator:  
n/a  
 
• DSMB: n/a  
 
CEC = Clinical Events Committee; DSMB = Data and Safety Monitoring Board; n/a = not applicable; PCI = percutaneous coronary intervention.   
* As per protocol, the relationship between an adverse vent and the study drug was assessed by the local investigator as well as the DSMB in case of reported 
serious adverse events.      
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Appendix Table 11. Outcomes for inflammatory biomarkers    
  All patients Evolocumab Placebo Mean difference p value 
hs-CRP       
Baseline (mg/L) 6.65 ± 5.98 [305] 6.68 ± 5.89 [153] 6.63 ± 6.09 [152] 0.06 (-1.28 to 1.40) 0.93 
Week 8 (mg/L)  2.46 ± 3.48 [291] 2.69 ± 3.83 [141] 2.23 ± 3.11 [150] 0.46 (-0.34 to 1.26) 0.26 
Absolute change (baseline to week 8) -3.99 ± 6.53 [289] -3.47 ± 6.53 [139] -4.47 ± 6.51 [150] 0.98 (-0.52 to 2.48) 0.20 
% Change (baseline to week 8)  -25.35 ± 194.67  -14.87 ± 255.75 [139] -35.07 ± 111.67 [150] 19.65 (-25.16 to 64.46) 0.39 
hs-CRP level <2 mg/L at week 8 (%)  69.1% [291] 68.8% [141] 69.3% [150] -0.7% (9.9% to -11.4%) 0.89 
Interleukin-1β      
Baseline (pg/ml) n = 302, 1.07 ± 0.72 n = 151, 1.06 ± 0.85 n = 151, 1.08 ± 0.57 -0.02 (-0.18 to 0.15) 0.85 
Week 8 (pg/ml) n = 289, 1.12 ± 1.45 n = 140, 1.16 ± 1.94 n = 149, 1.09 ±  0.74 0.07 (-0.27 to 0.40) 0.70 
Change (baseline to week 8) (pg/ml) n = 284, 0.02 ±  0.89 n = 136, 0.05 ± 0.90 n = 148, -0.01 ± 0.89 0.06 (-0.14 to 0.27) 0.55 
Interleukin 6 (pg/ml)            
Baseline (pg/ml) n = 303, 13.66 ± 15.50 n = 151, 14.58 ± 13.87 n = 152, 12.75 ± 16.97 1.85 (-1.62 to 5.32) 0.30 
Week 8 (pg/ml) n = 289, 3.78 ± 5.34 n = 140, 4.02 ± 6.08 n = 149, 3.55 ± 4.56 0.49 (-0.74 to 1.72) 0.43 
Change (baseline to week 8) (pg/ml)   n = 285, 9.63 ±  14.92 n = 136, 9.95 ± 14.62 n = 149, 9.34 ± 15.23 0.59 (-2.87 to 4.05) 0.74 
 
Data expressed as mean ± standard deviation or n (%). P-value of the randomised arm, using mixed models correcting for a random effect of the site and 
a fixed effect of stable statin treatment 4 weeks before randomisation.   
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